Nalbuphine N-oxide

Drug Profile

Nalbuphine N-oxide

Alternative Names: DUP 769

Latest Information Update: 18 Feb 2003

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Endo Pharmaceuticals
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine; Postoperative pain

Most Recent Events

  • 18 Feb 2003 Discontinued - Preclinical for Postoperative pain in USA (unspecified route)
  • 18 Feb 2003 Discontinued - Preclinical for Migraine in USA (unspecified route)
  • 09 Apr 1999 A study has been added to the pharmacokinetic section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top